2023-01-25 06:30:00

Poxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment o

Logo Benzinga
Benzinga
By Business Wire

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that European Commission has granted orphan drug designation (ODD) for PXL770 and PXL065 for the treatment of adrenoleukodystrophy (ALD). The decision follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). The U.S. Food and Drug Administration has previously granted ODD and Fast Track Designation to both PXL770 and PXL065 for the treatment of ALD.

These molecules have separate and distinct mechanisms of action. PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. PXL065 is a novel, proprietary deuterium-stabilized R-stereoisomer of pioglitazone which exerts effects via multiple non-genomic pathways engaged by thiazolidinedione molecules. Both compounds are preparing to enter into Phase 2a clinical Proof-of-Concept (POC) biomarker studies in ALD patients with adrenomyeloneuropathy (AMN) as soon as possible, subject to financing.

Continue read on benzinga.com

Logo PR Newswire
HealthPress Release2023-01-24 17:14:00
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 17:14:00
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
Amolyt to advance pre-clinical development of anti-PTHR1 monoclonal antibodies as potential treatments of primary hyperparathyroidism (PHPT) and humoral...

Logo GlobeNewswire
SciencePress Release2023-01-23 18:25:00
Announced Earlier Today -Notice Received from ANDA Filer for FIRDAPSE CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc....

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the Company, Finch, or Finch Therapeutics) (Nasdaq: FNCH) today...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 10:00:00
ATUM, a global specialist and industry leader in bioengineering solutions, today announced the signing of a full licensing agreement for the Leap-In...

Logo EIN Presswire
SAINT LOUIS, MISSOURI, USA, January 24, 2023 / EINPresswire.com / -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and...

Logo GlobeNewswire
SciencePress Release2023-01-24 12:30:00
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...

Logo GlobeNewswire
SciencePress Release2023-01-24 08:00:00
Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets LUGANO, Switzerland and...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 21:01:00
Second-Line GIST Patients with Mutations in KIT Exon 11 + 17/18 Only Demonstrated Substantial Clinical Benefit from QINLOCK but Not Sunitinib Company Plans...

Logo GlobeNewswire
SciencePress Release2023-01-24 12:00:00
Data Represent Research and Development Work Being Conducted at Tonixs Infectious Disease R&D Center (RDC) in Frederick, Md. CHATHAM, N.J., Jan. 24, 2023...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:30:00
ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple Myeloma SOUTH SAN...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 12:36:00
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix, Inc., a privately...

Logo PR Newswire
HealthPress Release2023-01-24 15:30:00
The dynamics of the dermatomyositis market are anticipated to change in the coming years owing to the improvement in the rise in a number of healthcare...

Logo EIN Presswire
Butchertown Clinical Trials facility in Louisville, Kentucky Butchertown Clinical Trials and The Eye Care Institute Announce Our 17th FDA Approval or...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 06:00:00
Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between...

Logo Nasdaq
Business / FinanceBy Rtt News2023-01-24 10:06:59
(RTTNews) - Alvotech (ALVO) and Bioventure Tuesday announced manufacturing and distribution approval of AVT02, a biosimilar of Humira, by the Saudi Food and...

Logo PR Newswire
HealthPress Release2023-01-24 08:00:00
Belgium team to expand under Country Manager, Dr Pierre-Hervé Brun, providing CNS treatments to patients BRUSSELS and DÜSSELDORF, Germany, Jan. 24, 2023...

Logo PR Newswire
HealthPress Release2023-01-24 11:30:00
DUBLIN, Jan. 24, 2023 /PRNewswire/ -- The "China Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's...